PL2452189T3 - Sposób identyfikacji związków do leczenia raka - Google Patents
Sposób identyfikacji związków do leczenia rakaInfo
- Publication number
- PL2452189T3 PL2452189T3 PL10730456T PL10730456T PL2452189T3 PL 2452189 T3 PL2452189 T3 PL 2452189T3 PL 10730456 T PL10730456 T PL 10730456T PL 10730456 T PL10730456 T PL 10730456T PL 2452189 T3 PL2452189 T3 PL 2452189T3
- Authority
- PL
- Poland
- Prior art keywords
- identification
- compounds
- treating cancer
- cancer
- treating
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200930417A ES2368963B1 (es) | 2009-07-04 | 2009-07-04 | Procedimiento de identificación de agentes terapéuticos contra el melanoma y uso de agente identificado. |
| EP10730456.0A EP2452189B1 (en) | 2009-07-04 | 2010-07-05 | Process for the identification of compounds for treating cancer |
| PCT/EP2010/059593 WO2011003883A1 (en) | 2009-07-04 | 2010-07-05 | Process for the identification of compounds for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2452189T3 true PL2452189T3 (pl) | 2014-05-30 |
Family
ID=42556459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10730456T PL2452189T3 (pl) | 2009-07-04 | 2010-07-05 | Sposób identyfikacji związków do leczenia raka |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20120172581A1 (pl) |
| EP (1) | EP2452189B1 (pl) |
| JP (2) | JP5908398B2 (pl) |
| KR (1) | KR101877840B1 (pl) |
| CN (3) | CN104857016B (pl) |
| AU (1) | AU2010270291B2 (pl) |
| BR (1) | BR112012000098B1 (pl) |
| CA (1) | CA2767148C (pl) |
| DK (1) | DK2452189T3 (pl) |
| ES (2) | ES2368963B1 (pl) |
| IL (1) | IL217310A (pl) |
| MX (1) | MX2012000280A (pl) |
| NZ (1) | NZ597793A (pl) |
| PL (1) | PL2452189T3 (pl) |
| PT (1) | PT2452189E (pl) |
| SG (1) | SG177482A1 (pl) |
| WO (1) | WO2011003883A1 (pl) |
| ZA (1) | ZA201200116B (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9572820B2 (en) | 2011-05-10 | 2017-02-21 | Stc.Unm | Methods of treating autophagy-associated disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits |
| KR102589295B1 (ko) | 2014-05-14 | 2023-10-13 | 타르그이뮨 테라퓨틱스 아게 | 개선된 폴리에틸렌이민 폴리에틸렌글리콜 벡터 |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| EP3319587B1 (en) * | 2015-11-17 | 2019-08-21 | Bioncotech Therapeutics, S.L | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
| CN114632091A (zh) * | 2016-04-01 | 2022-06-17 | 依生生物制药(新加坡)私人有限公司 | 用于治疗癌症的含有聚核苷酸的药物组合物 |
| US10849921B2 (en) | 2017-05-17 | 2020-12-01 | Bioncotech Therapeutics Sl | Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
| CN109200056A (zh) * | 2018-11-20 | 2019-01-15 | 苏州系统医学研究所 | 聚肌胞在防治胰腺炎及其相关病症中的用途 |
| WO2020104628A1 (en) | 2018-11-21 | 2020-05-28 | Bioncotech Therapeutics S.L | Nanoplexed poly(i:c) formulations and uses thereof |
| US12287338B2 (en) * | 2019-11-27 | 2025-04-29 | Ascentage Pharma (Suzhou) Co., Ltd. | Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway |
| CN111166769B (zh) * | 2020-03-18 | 2022-01-11 | 山东大学 | 真皮成纤维细胞在治疗黑色素瘤中的应用 |
| CA3182874A1 (en) * | 2020-06-15 | 2021-12-23 | Karina BETTEGA FELIPE | Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) and chemotherapy agents |
| WO2022111829A1 (en) | 2020-11-30 | 2022-06-02 | Symrise Ag | Essential oils of citrus fruits for use as medicament for induced, increased and/or accelerated autophagy in human keratinocytes |
| CN113413460A (zh) * | 2021-08-10 | 2021-09-21 | 中山大学·深圳 | Traf6抑制剂在制备黑色素瘤药物中的应用 |
| KR102747085B1 (ko) * | 2022-09-16 | 2024-12-27 | 재단법인 아산사회복지재단 | 자가포식 조절제를 스크리닝하는 방법 |
| WO2025202219A1 (en) * | 2024-03-25 | 2025-10-02 | Institut National de la Santé et de la Recherche Médicale | Mda5 inhibition as a broad defense and healthspan extending strategy |
| CN119925643A (zh) * | 2025-01-23 | 2025-05-06 | 中国科学院生物物理研究所 | 提高lsh含量或活性的物质在提高异染色质稳定性与增强细胞治疗疗效中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4124702A (en) * | 1971-07-06 | 1978-11-07 | Merck & Co., Inc. | Polynucleotides active as inducers of interferon production in living animal cells |
| DE19960206A1 (de) * | 1999-12-14 | 2001-07-19 | Frank Czubayko | Komplexierung von RNS mit Polyethyleniminen zur deren Stabilisierung und zellulären Einschleusung |
| US7229822B1 (en) * | 2000-02-29 | 2007-06-12 | Univ Columbia | Melanoma differentation associated gene-5 and vectors and cells containing same |
| EP1476199A2 (en) * | 2002-02-14 | 2004-11-17 | Research Development Foundation | Inhibition of lung metastases by aerosol delivery of p53 gene and anti-cancer compounds |
| US7927792B2 (en) * | 2002-11-18 | 2011-04-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Targeted double stranded RNA mediated cell killing |
| CA2548992A1 (en) * | 2003-12-11 | 2005-08-11 | Vaxdesign Corporation | Immunotherapy compositions, method of making and method of use thereof |
| US20080220416A1 (en) * | 2004-05-20 | 2008-09-11 | The Board Of Trustees Of The University Of Illinoi | Compositions for Inhibiting Cell Growth and Inducing Apoptosis in Cancer Cells and Methods of Use Thereof |
| CA2567526A1 (en) * | 2004-05-26 | 2005-12-15 | Wisconsin Alumni Research Foundation | Cancer treatment method by inhibiting mage gene expression or function |
| WO2006119619A1 (en) * | 2005-05-06 | 2006-11-16 | Replicor Inc. | Oligonucleotides inhibiting cell proliferation |
| CN101182517A (zh) * | 2007-12-18 | 2008-05-21 | 广州拓谱基因技术有限公司 | 用于疾病治疗的多靶点鸡尾酒双链小干扰rna及其制备方法 |
-
2009
- 2009-07-04 ES ES200930417A patent/ES2368963B1/es active Active
-
2010
- 2010-07-05 CN CN201510106426.XA patent/CN104857016B/zh active Active
- 2010-07-05 MX MX2012000280A patent/MX2012000280A/es active IP Right Grant
- 2010-07-05 AU AU2010270291A patent/AU2010270291B2/en active Active
- 2010-07-05 PT PT107304560T patent/PT2452189E/pt unknown
- 2010-07-05 PL PL10730456T patent/PL2452189T3/pl unknown
- 2010-07-05 CN CN2010800300491A patent/CN102483404A/zh active Pending
- 2010-07-05 WO PCT/EP2010/059593 patent/WO2011003883A1/en not_active Ceased
- 2010-07-05 CN CN201911209988.1A patent/CN110974842B/zh active Active
- 2010-07-05 JP JP2012516800A patent/JP5908398B2/ja active Active
- 2010-07-05 EP EP10730456.0A patent/EP2452189B1/en active Active
- 2010-07-05 DK DK10730456.0T patent/DK2452189T3/da active
- 2010-07-05 CA CA2767148A patent/CA2767148C/en active Active
- 2010-07-05 BR BR112012000098-5A patent/BR112012000098B1/pt active IP Right Grant
- 2010-07-05 US US13/382,092 patent/US20120172581A1/en not_active Abandoned
- 2010-07-05 ES ES10730456.0T patent/ES2442623T3/es active Active
- 2010-07-05 NZ NZ597793A patent/NZ597793A/xx unknown
- 2010-07-05 SG SG2012000212A patent/SG177482A1/en unknown
- 2010-07-05 KR KR1020127003104A patent/KR101877840B1/ko active Active
-
2012
- 2012-01-01 IL IL217310A patent/IL217310A/en active IP Right Grant
- 2012-01-06 ZA ZA2012/00116A patent/ZA201200116B/en unknown
-
2013
- 2013-05-28 US US13/903,380 patent/US20140154202A1/en not_active Abandoned
-
2015
- 2015-12-07 JP JP2015238154A patent/JP6222749B2/ja active Active
-
2016
- 2016-03-23 US US15/078,974 patent/US20170020917A1/en not_active Abandoned
-
2018
- 2018-09-12 US US16/129,147 patent/US20190134077A1/en not_active Abandoned
- 2018-12-11 US US16/216,714 patent/US20190117685A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201200116B (en) | Process for the identification of compounds for treating cancer | |
| PT3517534T (pt) | Compostos uteis para o tratamento de cancro | |
| PL2303021T3 (pl) | Związki do leczenia nowotworu | |
| IL213761A0 (en) | Novel ortho-aminoamides for the treatment of cancer | |
| IL213398A0 (en) | Compounds for treating cancer | |
| IL218633A0 (en) | Methods for treating psoriasis | |
| EP2477635A4 (en) | METHODS OF TREATING CEREBRAL TUMORS | |
| IL218230A0 (en) | Method of treating cancer | |
| IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
| PT2519231T (pt) | Inibidores do proteassoma para tratamento do cancro | |
| PT2509599E (pt) | Processo para o tratamento de cancro pancreático | |
| ZA201201894B (en) | Pharmaceutical combination for treating tumor | |
| AP2011005893A0 (en) | Thia-triaza-cyclopentazulenes as P13-kinases inhibitors for the treatment of cancer. | |
| EP2538944A4 (en) | METHOD FOR TREATING BRAIN TUMORS | |
| GB0914322D0 (en) | Compounds for treating cancer | |
| ZA201200981B (en) | Process for the treatment of ethylene |